Sublingual Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Sublingual tablet plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹6.0 crore - ₹71 crore CapEx this DPR captures:

• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The sublingual tablet sector in India operates within the broader oral solid dosage (OSD) and fast-dissolving tablet framework. Specific manufacturing capacity for sublingual tablets in India is typically aggregated under oral solids or orally disintegrating tablet (ODT) production lines, with no centralized national register of sublingual-specific capacity. Manufacturers such as Taj Pharma India Ltd., founded in the 2000s and operating out of Vapi, Gujarat, produce sublingual formulations including Buprenorphine Sublingual Tablets in 2 mg and 8 mg variants.

Centurion Remedies Private Limited, a Vadodara, Gujarat-based manufacturer active since approximately 2004, produces sublingual dosage lines. BonAyu Lifesciences, founded in 2015 in Bangalore, specializes in advanced alternative oral drug delivery platforms including thin strips and rapid-dissolve technologies handling dosage limits up to 500 mg.</p><p>India recorded approximately 103 verified export shipments of sublingual tablets tracked up to April 2026, with 14 verified Indian exporters and 18 active global buyers. This compares to the broader pharmaceutical tablet sector, which encompasses 19,631 export shipments involving 383 exporters and 451 buyers.

Western and Southern India dominate domestic consumption and advanced drug delivery infrastructure, with these regions housing the majority of specialized formulation facilities. Consumer preferences in India increasingly favor rapid absorption, water-free administration, and enhanced convenience, shifting demand toward fast-dissolving and orodispersible delivery mechanisms. Growth is heavily anchored by the rising elderly demographic and an expanding base of chronic disease patients requiring high medication adherence.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Sublingual tablet manufacturing requires specialized equipment and formulation technology to ensure rapid disintegration and bioavailability through mucosal absorption. High-volume rotary tablet press systems, such as the GEA Group PERFORMA D introduced in 2025, are implemented to scale oral solid dose manufacturing while meeting precise weight and thickness tolerances specific to sublingual variants. Environmental control demands strict facility-level relative humidity management, as moisture control is critical to sublingual tablet stability and dissolution performance.

Quality by Design frameworks aligned with ICH Q8, Q9, and Q10 guidelines are adopted to manage Critical Process Parameters and Critical Quality Attributes specific to sublingual mucosa disintegration and rapid dissolution.</p><p>The tablet compression and sublingual plant equipment market in India sees domestic manufacturers holding majority share in mid-range and entry-level segments, while imported equipment from Europe, Japan, and parts of East Asia accounts for 35% to 50% of volume share in high-precision, high-speed, and specialized segments. Component-level domestic manufacturing is well-developed, supporting the mid-range equipment ecosystem. In pharmaceutical manufacturing plants, HVAC motor systems consume 60% to 70% of total electrical energy.

Implementing strategic motor management policies and variable speed drives reduces overall plant energy consumption by 2% to 30%, representing a significant operational efficiency opportunity for new facilities.</p><p>Direct compression and granulation technologies form the backbone of sublingual tablet production, with continuous-flow manufacturing emerging as an innovation trend. The manufacturing unit labor structure per feasibility standards includes one Manufacturing Chemist, two Production Supervisors, and ten Skilled Workers, with additional unskilled workers as needed. Adherence to FDA 21 CFR Part 211 and EU GMP Chapter 5 mandates specialized validation, quality assurance, and mechanical calibration personnel.

Automated solid-dose manufacturing plants require capital expenditure on equipment representing 30% to 40% of total project cost, with individual core machines constituting significant capital line items.</p>

The ₹6 crore to ₹71 crore CapEx envelope for the sublingual tablet project aligns with SIDBI's pharmaceutical manufacturing infrastructure schemes offering term loans at 8.5-9.5 percent for MSE units and 9.0-10.5 percent for larger enterprises. SIDBI's Pharma Tech Fund provides specific assistance for WHO-GMP equipment procurement with 90 percent loan coverage. For projects exceeding ₹25 crore requiring USFDA audit readiness, ICICI Bank's healthcare and pharma vertical offers structured financing with ECB-linked pricing for imported European equipment, reducing effective interest costs by 150-200 basis points versus rupee term loans.

The PLI Scheme for Bulk Drugs and Medical Devices, extended in 2024 to include formulations, provides production-linked incentives of 3-8 percent of incremental sales to eligible manufacturers meeting ₹100 crore annual threshold. For a 2 billion tablet facility targeting ₹80 crore first-year revenue, PLI entitlement could reach ₹4-6.4 crore annually for five years post Qualifying Investment thresholds. State-level incentives from Gujarat Pharma Policy 2020 and Telangana's pharmaceutical cluster development scheme offer additional stamp duty exemption, power tariff subsidy of ₹1-2 per unit for five years, and land conversion fee waivers at designated pharma SEZs.

Debt-equity recommendation across capacity scenarios: 70:30 for minimum scale ₹6 crore project with SIDBI and regional rural bank consortium, tightening to 60:40 for ₹35 crore intermediate scenario with ICICI or Axis Bank lead, and 55:45 for maximum ₹71 crore deployment with SBI as lead arranger alongside SIDBI parallel commitment. Working capital cycle of 85-95 days comprises 45 days raw material inventory, 25 days work-in-progress for multi-layer tablet processes, and 15 days finished goods buffer accounting for batch-wise quality control release intervals.

<p>Manufacturing technical risks are significant for sublingual tablet production. Capping and lamination, caused by excessive compression force, high turret speeds, or inadequate binder concentrations, can lead to horizontal splitting and multi-layer structural failures, directly impacting yield. Picking and sticking, where materials adhere to punch faces and die walls during compression, requires precise formulation engineering and equipment maintenance protocols.

The critical nature of moisture control for sublingual tablet stability means that HVAC failures or environmental control lapses can result in entire batch losses. Given that raw materials and APIs account for 75% to 85% of operating expenses, raw material price volatility and supply chain disruptions pose meaningful margin risks.</p><p>Regulatory compliance represents an ongoing operational risk. The revised Schedule M implemented from 2024 to 2026, with requirements for Quality Risk Management, ALCOA-plus data integrity, and computerized system validation, demands continuous investment in quality systems and personnel training.

Meeting WHO-GMP, PIC/S, US FDA, and EU GMP standards for export markets requires sustained capital expenditure on facility maintenance, equipment calibration, and documentation infrastructure. For brownfield investments exceeding 74% FDI, mandatory government approval adds timeline and approval uncertainty.</p><p>Market competition from substitute delivery formats including ODTs, buccal medications, and effervescent tablets creates demand-side risk. While the overall fast-dissolving segment is growing, sublingual tablets at 32.1% market share of fast-dissolving tablets face substitution pressure from alternative oral delivery mechanisms.

The absence of a centralized sublingual-specific capacity register in India creates opacity in market sizing and competitive intelligence. GST treatment at 5% for the product versus 18% for manufacturing machinery creates a cost structure asymmetry. Energy costs, with HVAC consuming 60% to 70% of total electrical energy, represent a significant and rising operating expense that directly impacts the 5% to 12% net profit margin range.

Contract manufacturing pricing pressures from large CDMO buyers and the capital intensity of equipment at 30% to 40% of total project cost for mid-scale facilities add further financial risk dimensions.